3 Quantum Stocks to Buy If You Already Have IonQ

The article highlights Rigetti, Infleqtion and D-Wave as quantum-computing alternatives to IonQ, emphasizing government backing, AI data-center integration and technical progress despite weak current profitability. Rigetti received $100 million in CHIPS Act funding but posted just $5.1 million of Q2 revenue and a $28.1 million operating loss; Infleqtion secured a $20 million NASA contract and partners with Nvidia on quantum-enabled AI data centers. D-Wave reported first-half bookings up 1,120% year over year, a $35.5 million pipeline and growing commercial adoption, though the article cautions that pure-play quantum valuations remain disconnected from present financial fundamentals.

Analysis

This is primarily a liquidity-and-narrative trade, not a fundamental re-rating. The pure-play quantum cohort is likely to remain highly correlated to retail risk appetite, AI-capex headlines, and government-contract announcements; company-specific revenue comparisons are presently too small and lumpy to justify durable relative valuation gaps. The most investable second-order beneficiary is NVDA: any credible hybrid quantum/AI workflow increases the addressable software, networking, simulation, and accelerated-computing stack without requiring NVDA to underwrite quantum-hardware commercialization risk.

RGTI's public-sector alignment can lower financing risk relative to unbacked hardware peers, but it does not eliminate dilution risk: capital intensity and long commercialization cycles make equity issuance the dominant downside pathway over the next 6-18 months. QBTS has the cleaner near-term setup if enterprise bookings convert into recognized revenue, because commercial validation can support a multiple premium over research-led peers; however, its pipeline should be discounted heavily until conversion, renewal, and gross-margin data are visible. For INFQ, NASA and NVDA association are useful credibility signals, but neither establishes recurring data-center revenue or proves neutral-atom scalability at production economics.

Consensus appears to be extrapolating technical milestones directly into broad commercial adoption. The bottleneck is likely error-correction overhead, application integration, and customer willingness to pay for an advantage over GPU/HPC alternatives, not merely qubit quality; that favors platform incumbents AMZN and MSFT over hardware specialists over a multi-year horizon. A sharp reversal in speculative technology, delayed government appropriations, or another equity raise would likely compress the entire basket within days, while a disclosed paid production deployment or material cloud-service consumption commitment would be the key 1-3 month upside catalyst.

Key Decisions for Investors

• Do not initiate directional exposure to RGTI, QBTS, INFQ, or IONQ solely on this narrative; treat them as a high-beta thematic basket and require evidence of contracted backlog conversion, customer concentration, cash runway, and share-count trajectory before sizing.
• Prefer long NVDA versus a short equal-dollar basket of IONQ/RGTI/QBTS for a 3-6 month relative-value expression, entered only after a quantum-led spike in the pure plays. NVDA monetizes enabling compute demand today, while the short leg is vulnerable to financing and multiple compression; cover the short basket on a verified large commercial contract or government procurement award.
• Keep AMZN and MSFT on a 6-18 month watch list rather than buying for quantum optionality. Upgrade the thesis only if quantum services begin producing separately disclosed cloud consumption or enterprise workload migration; absent that disclosure, quantum remains immaterial to valuation.
• For QBTS specifically, monitor the next earnings release for pipeline-to-revenue conversion and gross-margin progression. A material bookings increase without revenue conversion or a worsening cash-burn outlook would support a tactical short; a meaningful multi-year enterprise contract with disclosed economics would falsify that bearish setup.